Onc.AI builds a digital clinical management platform that leverages radiomics and deep learning to support medical oncologists and advance immuno-oncology research. The company has assembled a real-world data asset focused on immuno-oncology that enabled development of a suite of AI models for clinical decision-making. Onc.AI is targeting commercialization of its first product in lung cancer and is prioritizing development and regulatory milestones ahead of that launch. Proceeds from the recent financing will also support active and future research collaborations with global pharmaceutical partners. The company is described in filings from San Carlos, California and Waterloo, Ontario and is led by co-founder and CEO Akshay Nanduri. Onc.AI is backed by a mix of venture investors and individual investors with expertise in enterprise SaaS, AI/drug-discovery, precision/medical oncology, and radiology. Onc.AI builds a precision oncology care management platform intended to transform clinical decision making and oncology diagnostics. The company develops deep‑learning driven tools to deliver actionable insights for oncology treatment and decision support. Its founding team includes operating executives, technologists and repeat entrepreneurs from healthcare, AI, autonomous driving and oncology. An advisory board of leading researchers and medical oncologists supports product development, including Dr. Hugo Aerts and Dr. George Simon. Onc.AI plans to expand its team in the Bay Area and Waterloo region and execute its operating plan to demonstrate its clinical solutions at leading cancer centers and health systems. The company recently closed a $6M financing round to support those plans.

Total raised

$31M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2023